Charles River
CRL
Performance
About Charles River
Charles River provides essential early-stage drug development and preclinical research services, specializing in animal models, toxicology, and translational biology to support biopharmaceutical discovery and development. With global laboratories and vivarium facilities, they offer expertise in in vivo pharmacology, pharmacokinetics, and bioanalysis to advance medicines from early discovery to candidate selection. The company operates internationally, serving pharmaceutical, biotechnology, and academic clients across multiple regions.
Recent News
Thermo Fisher, Charles River Workforce Cuts; WuXi Signs Contract with Vertex
Opinion: For AI to Have Impact, the Industry Must Align on Data
Why Early Process Design Is Key to Cell and Gene Therapy Success
Here Are Tuesday's Biggest Analyst Calls: Apple, Tesla, Amazon, GM, Crocs, Viking, Alphabet, Ford & More
Wells Fargo Investment Institute Downgrades Energy Sector to 'Unfavorable' On Limited War Premium
Inspired Pulls New CFO From Ranks
Charles River CEO Jim Foster to Retire; Samsung Bio Buys a GSK Factory
Charles River Laboratories Acquires PathoQuest and K.F. (Cambodia)
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
The State of Biologics Testing Report 2026
Smarter AAVs Drive Gene Therapy’s Next Chapter
IQVIA Signs Agreement to Acquire Drug Discovery Assets From Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities
Syngene International Names Abhijit Zutshi as Chief Commercial Officer to Drive Global CRO Growth
Dietary Fructo-Oligosaccharides Dose-Dependently Modulate the Microbiome and Suppress Type 2 Lung Inflammation in a Murine Model of House Dust Mite-Induced Allergic Asthma
GI Partners Launches Rose BioSolutions After Acquiring Charles River Labs' CDMO and Cell Solutions